Abstract
Introduction: Migraine and depressive disorder are highly prevalent and disabling pathologies, which present bidirectional relationships of comorbidity. Common risk factors and pathophysiological mechanisms for both diseases have been described in the literature, as well as associations between them and their clinical presentation.
Methods: This text is a narrative literature review. The bibliographical material was found through different databases specialized in ??health sciences.
Results: Some risk factors are associated with both pathologies, and both share pathogenic factors, including functional, structural, genetic, epigenetic, hormonal changes, among others. Several of the preventive treatments that have shown efficacy in the treatment of migraine are medications or measures with an antidepressant effect.
Discussion: Considering the associations and common factors described in the literature, it becomes evident that in the approach to patients diagnosed with any of these pathologies, it may be beneficial to consider a possible migraine-depression comorbidity.
Conclusion: It is important to promote the screening of these two patients diagnosed with some, since it can have therapeutic implications and impact on quality of life.
References
Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, et al. Migraine. Nat Rev Dis Primers. 2022;8(1):2. https://doi.org/10.1038/s41572-021-00328-4
Gobel H. 1. Migraine [Internet]. ICHD-3 The International Classification of Headache Disorders, 3rd edition [citado 10 de junio de 2020]. Disponible en: https://ichd-3.org/1-migraine/
Monroe SM, Harkness KL. Major depression and its recurrences: life course matters. Annu Rev Clin Psychol. 2022;18:329-57. https://doi.org/10.1146/annurev-clinpsy-072220-021440
Amoozegar F. Depression comorbidity in migraine. Int Rev Psychiatry. 2017;29(5):504-15. https://doi.org/10.1080/09540261.2017.1326882
Zhang Q, Shao A, Jiang Z, Tsai H, Liu W. The exploration of mechanisms of comorbidity between migraine and depression. J Cell Mol Med. 2019;23(7):4505-13. https://doi.org/10.1111/jcmm.14390
Global burden of disease visualisations: Compare [Internet]. [citado 22 de junio de 2020]. Disponible en: https://www.thelancet.com/lancet/visualisations/gbd-compare
Silva Sieger FA, Zarruk Serrano JG, Silva Camargo S, Camacho P, Díaz Silva GA, Díaz Quijano FA, et al. Influence of anxiety and depression on migraine-related disability. Acta Neurol Colomb 2012;28(4):194-201.
Gómez-Restrepo C, Tamayo Martínez N, Bohórquez A, Rondón M, Medina Rico M, Rengifo H, et al. Trastornos depresivos y de ansiedad y factores asociados en la población adulta colombiana, Encuesta Nacional de Salud Mental 2015. Rev Colomb Psiquiatr. 2016;45(S1):58-67. https://doi.org/10.1016/j.rcp.2016.04.009
Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders-A national population-based study. Headache J Head Face Pain. 2008;48(4):501-16. https://doi.org/10.1111/j.1526-4610.2007.00993.x
Angus-Leppan H, Guiloff AE, Benson K, Guiloff RJ. Navigating migraine care through the covid-19 pandemic: an update. J Neurol. 2021;268(11):4388-95. https://doi.org/10.1007/s00415-021-10610-w
Reyes-Alvarez MT, Bancalari E, Santana Vargas AD, Velez K, Rodríguez-Leyva I, Marfil A, Miranda S, Zegarra-Valdivia JA. Impact of covid-19 pandemic lockdown on migraine patients in Latin America. Int J Environ Res Public Health. 2023;20(4):3598. https://doi.org/10.3390/ijerph20043598
Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174-82. https://doi.org/10.1016/S1474-4422(17)30435-0
Malhi GS, Mann JJ. Depression. The Lancet. 2018;392(10161):2299-312. https://doi.org/10.1016/S0140-6736(18)31948-2
Gudmundsson LS, Scher AI, Sigurdsson S, Geerlings MI, Vidal J-S, Eiriksdottir G, et al. Migraine, depression, and brain volume. Neurology. 2013;80(23):2138-44. https://doi.org/10.1212/WNL.0b013e318295d69e
Ma M, Zhang J, Chen N, Guo J, Zhang Y, He L. Exploration of intrinsic brain activity in migraine with and without comorbid depression. J Headache Pain.2018;19(1):48. https://doi.org/10.1186/s10194-018-0876-9
Bartova L, Meyer BM, Diers K, Rabl U, Scharinger C, Popovic A, et al. Reduced default mode network suppression during a working memory task in remitted major depression. J Psychiatr Res. 2015;64:9-18. https://doi.org/10.1016/j.jpsychires.2015.02.025
Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013;14(9):609-25. https://doi.org/10.1038/nrn3381
Baksa D, Gonda X, Juhasz G. Why are migraineurs more depressed? A review of the factors contributing to the comorbidity of migraine and depression. Neuropsychopharmacol Hung. 2017;19(1):37-44.
Yang Y, Ligthart L, Terwindt GM, Boomsma DI, Rodriguez-Acevedo AJ, Nyholt DR. Genetic epidemiology of migraine and depression. Cephalalgia. 2016;36(7):679-91. https://doi.org/10.1177/0333102416638520
Todd C, Lagman-Bartolome AM, Lay C. Women and migraine: the role of hormones. Curr Neurol Neurosci Rep. 2018;18(7):42. https://doi.org/10.1007/s11910-018-0845-3
Warnock JK, Cohen LJ, Blumenthal H, Hammond JE. Hormone-related migraine headaches and mood disorders: treatment with estrogen stabilization. Pharmacotherapy. 2017;37(1):120-8. https://doi.org/10.1002/phar.1876
Zarcone D, Corbetta S. Shared mechanisms of epilepsy, migraine and affective disorders. Neurol Sci. 2017;38(S1):73-6. https://doi.org/10.1007/s10072-017-2902-0
Maizels M, Aurora S, Heinricher M. Beyond neurovascular: migraine as a dysfunctional neurolimbic pain network. Headache. 2012;52(10):1553-65. https://doi.org/10.1111/j.1526-4610.2012.02209.x
Chen Z, Chen X, Liu M, Dong Z, Ma L, Yu S. Altered functional connectivity of amygdala underlying the neuromechanism of migraine pathogenesis. J Headache Pain. 2017;18(1):7. https://doi.org/10.1186/s10194-017-0722-5
Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain. 2017;18(1):37. https://doi.org/10.1186/s10194-017-0742-1
Friedman LE, Gelaye B, Bain PA, Williams MA. A systematic review and meta-analysis of migraine and suicidal ideation: Clin J Pain.2017;33(7):659-65. https://doi.org/10.1097/AJP.0000000000000440
Leo RJ, Singh J. Migraine headache and bipolar disorder comorbidity: A systematic review of the literature and clinical implications. Scand J Pain. 2016;11:136-145. https://doi.org/10.1016/j.sjpain.2015.12.002
Baldacci F, Lucchesi C, Cafalli M, Poletti M, Ulivi M, Vedovello M, et al. Migraine features in migraineurs with and without anxiety-depression symptoms: a hospital-based study. Clin Neurol Neurosurg. 2015;132:74-8. https://doi.org/10.1016/j.clineuro.2015.02.017
Oedegaard K, Neckelmann D, Mykletun A, Dahl A, Zwart J, Hagen K, et al. Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study. Cephalalgia. 2006;26(1):1-6. https://doi.org/10.1111/j.1468-2982.2005.00974.x
Tietjen GE, Brandes JL, Digre KB, Baggaley S, Martin V, Recober A, et al. High prevalence of somatic symptoms and depression in women with disabling chronic headache. Neurology. 2007;68(2):134-40. https://doi.org/10.1212/01.wnl.0000251195.55563.02
Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-32. https://doi.org/10.1136/jnnp.2009.192492
Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, et al. Prevalence and characteristics of allodynia in headache sufferers: A population study. Neurology. 2008;70. https://doi.org/10.1212/01.wnl.0000310645.31020.b1
Diener HC, Holle-Lee D, Nägel S, Dresler T, Gaul C, Göbel H, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci. 2019;3(1):2514183X1882337. https://doi.org/10.1177/2514183X18823377
Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol. 2019;21(4):18. https://doi.org/10.1007/s11940-019-0557-2
Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31(3):542-59. https://doi.org/10.1016/j.clinthera.2009.03.020
Wollmer MA, de Boer C, Kalak N, Beck J, Götz T, Schmidt T, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012;46(5):574-81. https://doi.org/10.1016/j.jpsychires.2012.01.027
Affatato O, Moulin TC, Pisanu C, Babasieva VS, Russo M, Aydinlar EI, et al. High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. J Transl Med. 2021;19(1):133. https://doi.org/10.1186/s12967-021-02801-w
Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med. 2015;8:79-86. https://doi.org/10.2147/IJGM.S70456
Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA injection on depression in chronic migraine. Headache. 2015;55(9):1218-24. https://doi.org/10.1111/head.12657
Vikelis M, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al. Effects of fremanezumab on psychiatric comorbidities in difficult-to-treat patients with chronic migraine: post hoc analysis of a prospective, multicenter, real-world Greek registry. J Clin Med. 2023;12(13):4526. https://doi.org/10.3390/jcm12134526
Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache J Head Face Pain 2006;46(9):1334-43. https://doi.org/10.1111/j.1526-4610.2006.00577.x
Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: A population-based case-control study. Neurology. 2000;55(5):629-35. https://doi.org/10.1212/WNL.55.5.629
Canuet L, Ishii R, Fernandez-Concepcion O, Iwase M, Takeda M. Severity of depressive symptoms as predictor of impairment of quality of life in chronic migraine: Comparison with episodic migraine. Psychiatry Clin Neurosci.2008;62(6):738-40. https://doi.org/10.1111/j.1440-1819.2008.01867.x
Rossi P, Di Lorenzo G, Malpezzi MG, Di Lorenzo C, Cesarino F, Faroni J, et al. Depressive symptoms and insecure attachment as predictors of disability in a clinical population of patients with episodic and chronic migraine. Headache J Head Face Pain. 2005;45(5):561-70. https://doi.org/10.1111/j.1526-4610.2005.05110.x
Seng EK, Seng CD. Understanding migraine and psychiatric comorbidity. Curr Opin Neurol. 2016;29(3):309-13. https://doi.org/10.1097/WCO.0000000000000309
Maurer DM, Raymond TJ, Davis BN. Depression: screening and diagnosis. Am Fam Physician. 2018;98(8):508-15.
Amoozegar F, Patten SB, Becker WJ, Bulloch AGM, Fiest KM, Davenport WJ, et al. The prevalence of depression and the accuracy of depression screening tools in migraine patients. Gen Hosp Psychiatry. 2017;48:25-31. https://doi.org/10.1016/j.genhosppsych.2017.06.006
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.